ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect ArriVent BioPharma to post earnings of ($0.78) per share for the quarter.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.18. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Stock Performance

Shares of AVBP opened at $19.60 on Thursday. The firm has a market capitalization of $666.71 million, a price-to-earnings ratio of -7.63 and a beta of 1.00. ArriVent BioPharma has a one year low of $14.35 and a one year high of $36.37. The stock’s fifty day moving average is $25.18 and its 200-day moving average is $26.82.

Analyst Ratings Changes

AVBP has been the topic of a number of research analyst reports. Guggenheim initiated coverage on ArriVent BioPharma in a report on Monday, March 10th. They set a “buy” rating and a $45.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of ArriVent BioPharma in a report on Friday, March 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $39.40.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.